Top

Reactions Weekly

Published in:

01-02-2020 | Imatinib | Case report

Imatinib

Development of resistance: 3 case reports

Published in: Reactions Weekly | Issue 1/2020

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

The patients were identified from table 3 of the article.

Lewandowski K, et al. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: A final report of the MAPTEST study. Polskie Archiwum Medycyny Wewnetrznej 119: 789-794, No. 12, Dec 2009. Available from: URL: http://doi.org/10.20452/pamw.843 CrossRef

Title: Imatinib
Development of resistance: 3 case reports
Publication date: 01-02-2020
Publisher: Springer International Publishing
Keywords: Imatinib
Chronic Myeloid Leukemia
Published in: Reactions Weekly / Issue 1/2020
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-020-75229-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Imatinib

Development of resistance: 3 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Multiple drugs

Immune-globulin

Enoxaparin sodium

Aspirin

Ipilimumab/nivolumab/pembrolizumab

Bisacodyl/furosemide/senna alexandrina